Caloric restriction improves glycemic control via the adiponectin-ceramide axis in non-obese men and women: the CALERIE™ 2 randomized controlled trial.
Summary
In a 24-month randomized trial in non-obese adults, caloric restriction improved glycemic control and implicated the adiponectin–ceramide axis as a key mediator. Findings suggest that changes in adiponectin and bioactive ceramides track metabolic benefits of CR in humans.
Key Findings
- Caloric restriction over 24 months improved glycemic control in non-obese adults.
- The adiponectin–ceramide axis emerged as a mechanistic mediator of CR’s metabolic benefits.
- Trial registration NCT00427193; non-blinded design with biomarker profiling.
Clinical Implications
Supports mechanistically informed lifestyle counseling by highlighting adiponectin–ceramide signaling as a potential biomarker axis to monitor or target during caloric restriction interventions.
Why It Matters
Provides human RCT evidence linking a defined lipid-hormonal axis to the metabolic benefits of caloric restriction, advancing mechanistic understanding with translational potential.
Limitations
- Non-blinded design may introduce behavioral and ascertainment biases.
- Generalizability may be limited to non-obese adults engaged in a structured CR program.
Future Directions
Validate the adiponectin–ceramide axis as a monitoring biomarker and explore pharmacologic modulation of ceramide metabolism to mimic CR benefits.
Study Information
- Study Type
- RCT
- Research Domain
- Pathophysiology
- Evidence Level
- I - Randomized controlled trial with extended follow-up providing high internal validity.
- Study Design
- OTHER